Lipidor Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 0/6
Lipidor's earnings have been declining at an average annual rate of -9.2%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 1.4% per year.
Key information
-9.2%
Earnings growth rate
-0.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 1.4% |
| Return on equity | -83.0% |
| Net Margin | -14,546.2% |
| Next Earnings Update | 28 Feb 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Lipidor makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -14 | 9 | 0 |
| 31 Mar 24 | 0 | -12 | 8 | 0 |
| 31 Dec 23 | 0 | -11 | 8 | 0 |
| 30 Sep 23 | 0 | -15 | 9 | 0 |
| 30 Jun 23 | 0 | -25 | 11 | 0 |
| 31 Mar 23 | 0 | -30 | 12 | 0 |
| 31 Dec 22 | 0 | -41 | 11 | 0 |
| 30 Sep 22 | 0 | -44 | 11 | 0 |
| 30 Jun 22 | 16 | -28 | 10 | 0 |
| 31 Mar 22 | 16 | -28 | 10 | 0 |
| 31 Dec 21 | 16 | -21 | 9 | 0 |
| 30 Sep 21 | 16 | -15 | 8 | 0 |
| 30 Jun 21 | 0 | -23 | 7 | 0 |
| 31 Mar 21 | 1 | -18 | 6 | 0 |
| 31 Dec 20 | 1 | -16 | 5 | 0 |
| 30 Sep 20 | 1 | -15 | 5 | 0 |
| 30 Jun 20 | 1 | -14 | 5 | 0 |
| 31 Mar 20 | 1 | -14 | 4 | 0 |
| 31 Dec 19 | 1 | -14 | 4 | 0 |
| 30 Sep 19 | 1 | -13 | 4 | 0 |
| 30 Jun 19 | 0 | -10 | 3 | 0 |
| 31 Mar 19 | 0 | -9 | 2 | 0 |
| 31 Dec 18 | 0 | -8 | 1 | 0 |
| 31 Dec 17 | 0 | -3 | 1 | 0 |
| 31 Dec 16 | 0 | -5 | 1 | 2 |
Quality Earnings: L7R is currently unprofitable.
Growing Profit Margin: L7R is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: L7R is unprofitable, and losses have increased over the past 5 years at a rate of 9.2% per year.
Accelerating Growth: Unable to compare L7R's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: L7R is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: L7R has a negative Return on Equity (-83.03%), as it is currently unprofitable.